smmt-20240402

0001599298-24-000051.txt : 20240403 0001599298-24-000051.hdr.sgml : 20240403 20240403164210 ACCESSION NUMBER: 0001599298-24-000051 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240402 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240403 DATE AS OF CHANGE: 20240403 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Summit Therapeutics Inc. CENTRAL INDEX KEY: 0001599298 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36866 FILM NUMBER: 24819545 BUSINESS ADDRESS: STREET 1: 2882 SAND HILL ROAD STREET 2: SUITE 106 CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650-460-8308 MAIL ADDRESS: STREET 1: 2882 SAND HILL ROAD STREET 2: SUITE 106 CITY: MENLO PARK STATE: CA ZIP: 94025 FORMER COMPANY: FORMER CONFORMED NAME: Summit Therapeutics plc DATE OF NAME CHANGE: 20150219 FORMER COMPANY: FORMER CONFORMED NAME: Summit Corp plc DATE OF NAME CHANGE: 20140205 8-K 1 smmt-20240402.htm 8-K smmt-20240402

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): April 2, 2024


Summit Therapeutics Inc.
(Exact Name of Registrant as Specified in Its Charter)

Delaware	001-36866	37-1979717
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

601 Brickell Key Drive, Suite 1000, Miami, FL		33131
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (650) 460-8308



(Former Name or Former Address, If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of Each Class	Trading Symbol(s)	Name of Each Exchange on Which Registered
Common stock, $0.01 par value per share	SMMT	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 5.02			Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 2, 2024, Ankur Dhingra, the principal financial officer and principal accounting officer of Summit Therapeutics Inc. (the “Company”), resigned as Chief Financial Officer of the Company. Mr. Dhingra’s resignation was not due to any disagreement with the Company relating to its operations, policies or practices.

In order to replace Mr. Dhingra, contemporaneously with Mr. Dhingra’s resignation, the Company appointed its Chief Operating Officer Manmeet Soni to the office of Chief Financial Officer, in which capacity he will serve as the Company’s principal financial officer, in addition to his continuing service as Chief Operating Officer. As compensation for Mr. Soni’s acceptance of the additional responsibility of serving as the Company’s principal financial officer, in addition to his existing compensation, he will receive a one-time cash bonus in the amount of $100,000 and 1,100,000 options to purchase shares of the Company’s common stock (“Common Stock”). The options granted to Mr. Soni shall vest in equal annual installments over a four-year period.

In addition, on April 2, 2024, the Company hired Bhaskar Anand as Chief Accounting Officer, Head of Finance, to serve as its principal accounting officer. Pursuant to his employment agreement with the Company, Mr. Anand will receive compensation comprised of (i) annual base salary of $430,000, (ii) a bonus opportunity of up to 40% of his annual base salary, subject to satisfaction of performance criteria to be determined and (iii) an award of 1,200,000 options to purchase shares of Common Stock. Of the options granted to Mr. Anand, half shall vest in equal annual installments over a four-year period and half shall vest subject to satisfaction of performance conditions based on market capitalization and revenue targets.

Mr. Soni, age 46, has served as Chief Operating Officer since October 2023 and as a member of the Company’s board of directors (the “Board”) since December 2019. Mr. Soni previously served as the President, Chief Operating Officer and Chief Financial Officer of Reata Pharmaceuticals, Inc., a role he held from February 2022 through September 2023, after initially joining Reata Pharmaceuticals as an executive officer in August 2019. Prior to joining Reata Pharmaceuticals, Mr. Soni was the Senior Vice President and Chief Financial Officer of Alnylam Pharmaceuticals Inc. from May 2017 to August 2019. Mr. Soni has served as a member of the board of directors of Pulse Biosciences, Inc. since November 2017 and previously served as a member of the board of directors of Arena Pharmaceuticals, Inc. from December 2018 to June 2021. Mr. Soni is a Certified Public Accountant and Chartered Accountant (India).

On October 13, 2023, Mr. Soni invested $5,000,000 in the Company in a private placement in exchange for 2,976,190 shares of Common Stock at a purchase price of $1.68 per share. Except as described herein, there are no arrangements or understandings between Mr. Soni and the Company pursuant to which he was appointed as principal financial officer and Chief Financial Officer and there are no related party transactions or family relationships required to be disclosed pursuant to Item 404(a) or Item 401(b) of Regulation S-K.

Mr. Anand, age 46, most recently served as SVP, Chief Accounting Officer (principal accounting officer) at Reata Pharmaceuticals, Inc. from July 2021 through December 2023 and has over twenty years of strategic and operational experience. Prior to joining Reata, Mr. Anand served as Corporate Controller of Juul Labs from August 2018 until May 2021. Mr. Anand is a Certified Public Accountant and Chartered Accountant (India). Mr. Anand is an experienced leader in transitioning rapid growth companies to self-sufficient global commercial enterprises and assisted with the execution of a $7.5 billion merger transaction with Biogen while at Reata.

Except as described herein, there are no arrangements or understandings between Mr. Anand and the Company pursuant to which he was appointed as principal accounting officer and Chief Accounting Officer, Head of Finance and there are no related party transactions or family relationships required to be disclosed pursuant to Item 404(a) or Item 401(b) of Regulation S-K.


Item 9.01			Financial Statements and Exhibits.

(d) Exhibits


Exhibit Number			Description
104			Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.


	SUMMIT THERAPEUTICS INC.


Date: April 3, 2024	By:	/s/ Robert W. Duggan
		Chief Executive Officer
		(Principal Executive Officer)

EX-101.SCH 2 smmt-20240402.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 3 smmt-20240402_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 4 smmt-20240402_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Former Address Former Address [Member] Document Period End Date Document Period End Date Entity Addresses, Address Type [Axis] Entity Addresses, Address Type [Axis] Pre-commencement Tender Offer Pre-commencement Tender Offer Entity Addresses [Table] Entity Addresses [Table] Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Addresses [Line Items] Entity Addresses [Line Items] Entity Central Index Key Entity Central Index Key Entity Address, City or Town Entity Address, City or Town Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol Address Type [Domain] Address Type [Domain] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Document Type Document Type Amendment Flag Amendment Flag Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name EX-101.PRE 5 smmt-20240402_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 R1.htm IDEA: XBRL DOCUMENT

Cover	Apr. 02, 2024
Entity Addresses [Line Items]
Document Type	8-K
Document Period End Date	Apr. 02, 2024
Entity Registrant Name	Summit Therapeutics Inc.
Entity Incorporation, State or Country Code	DE
Entity File Number	001-36866
Entity Tax Identification Number	37-1979717
Entity Address, Address Line One	601 Brickell Key Drive, Suite 1000
Entity Address, City or Town	Miami
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33131
City Area Code	(650)
Local Phone Number	460-8308
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common stock, $0.01 par value per share
Trading Symbol	SMMT
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false
Entity Central Index Key	0001599298
Amendment Flag	false

EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 1 22 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://www.summitplc.com/role/Cover Cover Cover 1 false false All Reports Book All Reports [dq-0540-DocumentPeriodEndDate-Value] In submission type 8-K, DocumentPeriodEndDate value 2024-04-02, is not equivalent to header element periodOfReport value, 04-03-2024, in the Required Context. smmt-20240402.htm 4 smmt-20240402.htm smmt-20240402.xsd smmt-20240402_def.xml smmt-20240402_lab.xml smmt-20240402_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "smmt-20240402.htm": { "nsprefix": "smmt", "nsuri": "http://www.summitplc.com/20240402", "dts": { "inline": { "local": [ "smmt-20240402.htm" ] }, "schema": { "local": [ "smmt-20240402.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "smmt-20240402_def.xml" ] }, "labelLink": { "local": [ "smmt-20240402_lab.xml" ] }, "presentationLink": { "local": [ "smmt-20240402_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 28, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://www.summitplc.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "smmt-20240402.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "smmt-20240402.htm", "first": true, "unique": true } } }, "tag": { "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AddressTypeDomain", "presentation": [ "http://www.summitplc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Address Type [Domain]", "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.summitplc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.summitplc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.summitplc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.summitplc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.summitplc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.summitplc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.summitplc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.summitplc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressesAddressTypeAxis", "presentation": [ "http://www.summitplc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Addresses, Address Type [Axis]", "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityAddressesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressesLineItems", "presentation": [ "http://www.summitplc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Addresses [Line Items]", "label": "Entity Addresses [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityAddressesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressesTable", "presentation": [ "http://www.summitplc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Addresses [Table]", "label": "Entity Addresses [Table]", "documentation": "Container of address information for the entity" } } }, "auth_ref": [ "r1" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.summitplc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.summitplc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.summitplc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.summitplc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.summitplc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.summitplc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_FormerAddressMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "FormerAddressMember", "presentation": [ "http://www.summitplc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Former Address", "label": "Former Address [Member]", "documentation": "Former address for entity" } } }, "auth_ref": [ "r6", "r7" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.summitplc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.summitplc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.summitplc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.summitplc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.summitplc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.summitplc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.summitplc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.summitplc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r8" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "249", "Section": "308", "Subsection": "a" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 8-K", "Number": "249", "Section": "308" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 16 0001599298-24-000051-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001599298-24-000051-xbrl.zip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end XML 18 smmt-20240402_htm.xml IDEA: XBRL DOCUMENT 0001599298 2024-04-02 2024-04-02 0001599298 false 8-K 2024-04-02 Summit Therapeutics Inc. DE 001-36866 37-1979717 601 Brickell Key Drive, Suite 1000 Miami FL 33131 (650) 460-8308 false false false false Common stock, $0.01 par value per share SMMT NASDAQ false